Mitophagy is a highly conserved cellular process that maintains the mitochondrial quantity by eliminating dysfunctional or superfluous mitochondria through autophagy machinery. The mitochondrial outer membrane protein BNIP3L/Nix serves as a mitophagy receptor by recognizing autophagosomes. BNIP3L is initially known to clear the mitochondria during the development of reticulocytes. Recent studies indicated it also engages in a variety of physiological and pathological processes. In this review, we provide an overview of how BNIP3L induces mitophagy and discuss the biological functions of BNIP3L and its regulation at the molecular level. We further discuss current evidence indicating the involvement of BNIP3L-mediated mitophagy in human disease, particularly in cancer and neurological disorders.

Cell Death and Disease (2022)13:14; https://doi.org/10.1038/s41419-021-04469-y

FACTS

- BNIP3L promotes mitophagy either via recruiting autophagosomes to target mitochondria or enhancing the formation of autophagosomes.
- BNIP3L-mediated mitophagy is regulated at the pre-transcriptional, posttranslational, and homodimerization of BNIP3L is required for its mitophagic activity.
- BNIP3L either participates in mitophagy independently or interplays with other autophagy/mitophagy pathways.
- BNIP3L involves in a variety of human diseases, including cancer, neurological, metabolic, and cardiovascular disorders.

INTRODUCTION

Mitochondrial quality control plays a central role in cellular homeostasis. Besides mitochondrial biogenesis, mitochondrial elimination via the autophagosome-lysosome pathway, which is frequently termed mitophagy, plays a crucial role in maintaining the cellular steady state of mitochondrial functions [1, 2]. Mounting evidence indicated the significance of appropriate mitophagy, either in terms of extension and specificity, in cell development and human diseases. To meet the needs of mitochondrial turnover, mammalian cells evolved a variety of molecular machineries. In particular, a multitude of mitophagy receptors connects target mitochondria with autophagosomes for degradation by sensing distinct intracellular or environmental stress [3]. These mitophagy receptors can be regulated at different stages of expression, translation, and post-translation, thus are able to regulate mitochondrial elimination precisely.

BNIP3L/Nix is a mitochondrial protein from the outer membrane that belongs to the BH3-only protein from the BCL2 family. BNIP3L was initially recognized as a proapoptotic protein with milder efficacy in inducing apoptosis compared to other proteins in this family [4, 5]. These phenotypes raised concerns about the molecular function of BNIP3L besides inducing apoptosis [4, 6]. A milestone disclosure in this field was made by the discovery that mice with a Bnip3 gene deletion showed a dysregulated maturation of the reticulocytes, in which massive mitochondria accumulated due to an impaired mitophagic process [7, 8]. BNIP3L has been accepted as a mitophagy receptor that binds to Atg8 proteins [9]. Nevertheless, it is not yet fully understood how BNIP3L-mediated mitophagy is regulated at the molecular level. Hypoxia has been considered as a canonical stress factor that induces BNIP3L-mediated mitophagy since BNIP3L can be transcriptionally upregulated by the hypoxia-inducible factor-1alpha (HIF1A). However, BNIP3L upregulation was not substantial in some cell types despite hypoxic conditions [10–13]. Instead, other transcription factors and non-coding RNAs reportedly regulated the transcription of Bnip3 by sensing distinct environmental fluctuations. More intriguingly, emerging data indicated that posttranslational modification of BNIP3L, in particular phosphorylation and ubiquitination, finely regulates BNIP3L-mediated mitophagy [14–16].

The significance of BNIP3L-mediated mitophagy was initially emphasized in the development of reticulocytes [7]. Since then,
accumulating evidence indicated the involvement of BNIP3L-mediated mitophagy in the development process of other cell types. The molecular mechanisms underlying BNIP3L-mediated mitophagy, however, have not yet been fully elucidated. BNIP3L might act as a mitophagy receptor by binding with LC3s; alternatively, it is possible that BNIP3L interferes with some other autophagy/mitophagy pathways, including BECN1, RHEB2, cardiolipin, and PRKN. Furthermore, it is now clear that problems in BNIP3L-mediated mitophagy are associated with a number of human diseases, including neurological disorders, metabolic diseases, and cancer. Unfortunately, due to a poor understanding of the association between BNIP3L-mediated mitophagy and different diseases, few studies addressed potential therapies. Here, we review BNIP3L-mediated mitophagy and discuss how this process is regulated at the molecular level. Furthermore, we update current perspectives on the role of BNIP3L in cell development and human diseases by integrating the findings from novel research studies.

**MITOCHONDRIA ELIMINATION BY AUTOPHagy**

Autophagy maintains intracellular metabolic balance by degrading superfluous and damaged intracellular substances. The process of autophagy has been described elegantly [17]. Briefly, the biogenesis of autophagosomes is initiated by forming phagophores. Autophagosomal membranes are then further extended during maturation and fuse with lysosomes to form autolysosomes, in which the engulfed cargoes are degraded. Autophagy has been widely accepted as a selective, rather than random, process to eliminate cargoes [18]. Mitophagy is essential for mitochondrial quality control. Accumulating evidence indicates mitophagy dysregulation in a variety of human diseases. Mitophagy is restrictively controlled by several proteins, including PINK1/PARKIN, BNIP3L, and FUNDC1, etc. by sensing distinct extracellular signaling, e.g., mitochondrial proteins, including PINK1/PARKIN, BNIP3L, and FUNDC1, etc. [20–32]. This leads to specific disease-related phenotypes [20–23]. Given that most of the mitophagy-related proteins have been elegantly summarized elsewhere [24–26], the regulatory mechanisms of BNIP3L, as a mitophagy receptor, and its association with human disease have not been carefully reviewed.

**BNIP3L-MEDIATED MITOPHAGY**

BNIP3L has been identified more than two decades ago [27, 28]. Sequencing analysis first recognized BNIP3L as a proapoptotic BCL2 family protein [29, 29] that could induce cell apoptosis or necrosis [30, 31]. Specifically, BNIP3L interacts with the proapoptotic Bcl2 family proteins BAX and BAK to increase the permeability of the mitochondrial outer membrane [32, 33]. This eventually leads to mitochondrial-dependent cell apoptosis. However, either endogenous or ectogenic BNIP3L expression has a poor influence on apoptotic cell death [34–36], compared to other BH3-only proapoptotic proteins [6]. BNIP3L has also been found in the endoplasmic reticulum (ER) [30], increasing its calcium storage through unknown mechanisms and promoting mitochondrial calcium uptake. The disruption of mitochondrial calcium homeostasis increases mitochondrial permeability and ultimately leads to cell demise [30, 37, 38].

Latterly the discovery of BNIP3L-promoted mitochondrial elimination by autophagy in developing reticulocytes opened a new horizon in BNIP3L research [7, 8]. BNIP3L-induced mitophagy has since been identified in natural killer cells, neurons, retinal ganglion cells, renal cells, and several types of tumor cells [16, 39, 40]. In addition, BNIP3L might be involved in mitophagy in muscle and some cancer cells, even though direct evidence is still absent [41].

One central question is how BNIP3L modulates mitophagy. BNIP3L disrupts the BCL2-BECN1 complex and releases BECN1, which promotes the formation of autophagosomes [42, 43]. BNIP3L also activates autophagy in epithelial cells from the respiratory tract [44]. Interestingly, BNIP3L-activated autophagy can be mimicked by a BH3 domain-like small molecule, which may serve as a promising drug [45, 46]. Furthermore, BNIP3L can inhibit MTORC1 to induce autophagy [47]. Interestingly, the gene plays a minimal role on the autophagy machinery of developing reticulocytes, ischemic brains, and hypoxic colon carcinoma [7, 16, 48]. Notwithstanding, BNIP3L plays a part in the regulation of autophagy activation, likely relying on the abundance of BECN1 or MTOR within distinct cell types.

The most well-accepted mechanism underlying BNIP3L-mediated mitophagy is through an interaction with proteins from the Atg8 family, by which BNIP3L recruits autophagosomes to targeted mitochondria [9, 49]. Two BNIP3L domains are required for mitophagy, an LIR domain and a transmembrane TM domain (Fig. 2). The LIR domain is composed of four amino acid motifs that are critical for the interaction with LC3s. The BNIP3L genetic sequence contains two LIR motifs, of which the one located at the C-terminus [31–34] is essential for mitophagy. The deletion of the LIR motif in BNIP3L led to a failure to induce mitophagy [3]. However, it was later demonstrated that the deletion of a specific motif known as the minimal essential region (MER), rather than LIR, inhibited BNIP3L-mediated mitophagy [50]. These observations indicated that the MER, but not the LIR motif, is essential for BNIP3L-induced mitophagy. The TM domain located in the C-terminus of BNIP3L allows for its mitochondrial location, and the BNIP3L presence in other organelles leads to organelle-specific autophagy [51]. The TM domain does not participate in the interaction between Atg8 proteins and the LIR motif [49]. Recent studies indicated that BNIP3L may serve as a tag to label the targeted mitochondria for degradation [14, 19, 16, 52], even though

![Fig. 1 An overview of the mitophagy process.](image-url)
that triggers mitophagy. Hence, BNIP3L seemingly induces which was considered a marker of dysfunctional mitochondria loss of mitochondrial transmembrane potential ($\Delta \Psi M$) [30, 53–55], which was considered a marker of dysfunctional mitochondria that triggers mitophagy. Hence, BNIP3L seemingly induces $\Delta \Psi M$ collapse and thus initiates mitophagy. However, this assumption was challenged by the observation that BNIP3L does not necessarily cause $\Delta \Psi M$ loss when serving as a mitophagy receptor [7, 56]. Intriguingly, a recent study showed Bnip3l silencing can reduce $\Delta \Psi M$ during programmed mitophagy in cardiac progenitor cells (CPS) [57]. The causal relation among BNIP3L presence, $\Delta \Psi M$ loss, and mitophagy should be further investigated. The PRKN/PARK2 can sense $\Delta \Psi M$ loss and ubiquitinate BNIP3L [58]. However, recent studies proposed BNIP3L does not functionally depend on PARK2 for manipulating mitophagy. In cells derived from patients suffering from Parkinson’s disease (PD), BNIP3L seemingly compensates for the loss-of-function mutation of PRKN/PARK2 and restores mitophagy [59]. Accordingly, BNIP3L (and not PRKN/PARK2) is involved in the programmed mitophagy of CPCs [57]. Furthermore, PARK2 deletion did not affect BNIP3L-induced mitophagy in ischemic neurons [16]. Finally, a recent study clearly demonstrated BNIP3L, rather than PARK2, is required for mitophagy clearance of axonal mitochondria [47]. These studies support distinct working mechanisms between BNIP3L and PARK2 and suggest $\Delta \Psi M$ loss may not be the most relevant trigger initiating BNIP3L-mediated mitophagy.

In summary, the role played by BNIP3L as a mitophagy receptor is now consensual, and extends beyond its function as a BH3 only proapoptotic protein. BNIP3L participates in mitophagy by promoting the formation of autophagosomes and, more directly, by recruiting them to target mitochondria. While the mechanistic details behind BNIP3L-mediated mitophagy need further elucidation, current evidence emphasizes BNIP3L is an independent mitophagy-inducing factor from the canonical PARK2.

REGULATIONS OF BNIP3L-MEDIATED MITOPHAGY

Distinct mitophagy receptors may sense specific cellular stresses in order to initiate mitophagy. However, the specific environmental cues sensed by BNIP3L to regulate the mitophagic process remain unknown. Hypoxia is known intimately to signal BNIP3L-mediated mitophagy given HIF1A activates the transcription of Bnip3l [48, 60–62]. Paradoxically, this hypothesis originated from the studies in BNIP3, a homologous BNIP3L protein. Both Bnip3 and Bnip3l were transcriptionally upregulated in CHO-K1 cells subjected to hypoxic conditions, but Bnip3l showed a considerably lower sensitivity to hypoxia [10], which was also observed in several tumor cell lines [11]. The assumption that hypoxia activates BNIP3L was further challenged by the observation that BNIP3L expression was neither related with pO2 in tumors [63] nor activated by ischemia in neurons or brain cells [16, 64]. In fact, hypoxia alone might not be sufficient to activate BNIP3L transcription [13, 35]. Some additional transcriptional factors such as TP53, FOXO3, PPARGC1A, E2F1, and FATE1 [34, 65–69], or other important growth factors [70] might be required for hypoxia-induced BNIP3L upregulation. Recent studies proposed that other cellular stresses or environment fluctuations are also involved in BNIP3L regulation. For example, BNIP3L transcription is activated by cytotoxic drugs [41, 71, 72], glucose level perturbations [73], and during the process of cell development [51, 56]. Mounting evidence indicated Bnip3l expression can be regulated by some micro RNAs, including miR-347, miR-30, miR-302/367, miR-133a, etc. [71, 74–76]. The regulation of BNIP3L by miRNAs was reviewed in previous work [77]. Recent data also proposed an epigenetic regulation of Bnip3l through DNA methylation [78, 79]. Therefore, BNIP3L expression can be regulated at both pre- and post-transcriptional levels and triggered by distinct cellular stresses including, but not limited to, hypoxia.

Current knowledge supports mitochondrial BNIP3L recruits autophagosomes needed for mitochondria degradation, which implies BNIP3L abundance is a decisive factor in mitophagy. However, BNIP3L is ubiquitously distributed on most mitochondria but only a portion of the BNIP3L-labeled mitochondria undergoes mitophagy. This paradigm is different from the PRKN/PARK2-induced mitophagy, in which PARK2 selectively accumulates on damaged mitochondria with low transmembrane potential to enable mitophagy. These observations raise the possibility that mechanisms other than location influence BNIP3L-mediated mitophagy.

Phosphorylation arguably remains the most carefully studied molecular mechanism behind BNIP3L-mediated mitophagy (Table 1). BNIP3L phosphorylation was initially found in a study identifying the CK2 substrate [80]. The Bnip3l serine residues S120, possibly S117 and S118 (by human sequence) as well, are phosphorylated by CK2, even though the functional significance of this phosphorylation remains unknown. Intriguingly, CK2 phosphorylation might also be a mechanism that regulates mitophagy receptor activity [81]. Our previous study identified a serine 81 (S81 in human BNIP3L) phosphorylation is required for BNIP3L-induced mitophagy. The biological significance of S81 phosphorylation was confirmed in ischemic brain cells, in which a Bnip3l S81A mutant failed to eliminate damaged mitochondria and aggravated ischemic neuronal injury [16]. The S81 phosphorylation of Bnip3l was recapitulated in a cadmium-mediated mitophagy in HeLa cells [82]. Crucially, this residue is located in the MER motif region and might serve an adapter essential for BNIP3L activity. The Bnip3l S81A mutant showed similar mitochondrial localization as the wild-type, but completely eliminated Bnip3l binding with LC3s and showed a limited enhancement of mitophagy induction [16]. This observation implied that unphosphorylated Bnip3l at S81
Table 1. Posttranslational modification (PTM) of BNIP3L and association with human disease.

| Types | Sites | Biological functions | Related diseases | Ref. |
|-------|-------|----------------------|------------------|------|
| Phosphorylation | S34, S35 | S34/35 phosphorylation enhances autophagosome recruitment to mitochondria | Hela cells (Undetermined disease) | [14] |
| | | | | |
| | S82 | S82 phosphorylation is required for BNIP3L-mediated mitophagy | Cerebral ischemia | [16] |
| | S118, S120 | Undetermined biological function | Undetermined related disease | [80] |
| | S212 | S212 phosphorylation disrupts BNIP3L dimerization | HEK293 and HeLa cells (Undetermined disease) | [83] |
| Ubiquitylation | Unknown | Ubiquitination of BNIP3L by PARK2 recruits NBR1 to perform mitophagy. | Parkinson’s disease | [52] |
| | | Proteasomal degradation of ubiquitylated BNIP3L leads to mitophagy deficiency | Cerebral ischemia | [15] |

Y. Li et al. BNIP3L, showed a significantly higher affinity to LC3B [14]. In addition, phosphomimetic mutations of BNIP3L (S34, 3SD or S34, 3SE) reinforced its mitophagic activity. Interestingly, we found the BNIP3L S34, 35D mutation does not promote mitophagy in ischemic neuronal cells (unpublished data). These different pieces of evidence suggest BNIP3L phosphorylation occurring at distinct serine residues may play different functions in different cell types. A recent study by Novak et al. identified the phosphorylation at BNIP3L serine 212 residue promoted the homodimerization of BNIP3L to induce mitophagy [83], which is discussed below. Taken together, these data support a model where phosphorylated BNIP3L serves as a tag on mitochondria targeted for elimination among the BNIP3L-labeled mitochondrial pool. However, the specific phosphatases and kinases involved in controlling BNIP3L phosphorylation remain unknown, but these enzymes may constitute promising drug targets for treating human diseases associated with mitophagy dysfunction.

Ubiquitylation is an alternative strategy for the selective elimination of BNIP3L-labeled mitochondria. BNIP3L can act as a PARK2 substrate, which is an E3 ubiquitin ligase. Ubiquitylated BNIP3L recruits the adapter protein NBR1 in the autophagosome to perform mitophagy [58]. This study thus provided an elegant illustration of how BNIP3L cooperates with PARK2 to induce mitophagy. We have also recently revealed an additional contribution of BNIP3L ubiquitylation to mitophagy regulation. Specifically, we identified a proteasomal degradation of ubiquitylated BNIP3L in ischemic brain cells that led to BNIP3L loss and mitophagy deficiency. The prevention of BNIP3L degradation by ubiquitin-proteasome inhibitors restored mitophagic activity and conferred neuroprotection [15]. We thus identified a novel mechanism through which BNIP3L-mediated mitophagy ceases under stressful conditions. We noted that the specific ubiquitylated BNIP3L lysine residues in these two scenarios remain unknown. This is also true for specific E3 ubiquitin ligases responsible for BNIP3L ubiquitylation besides PARK2. Such knowledge would help explore the distribution of E3 ligases within the mitochondria, particularly those associated with the regulation of mitophagy [84–86].

The transmembrane (TM) domain enables BNIP3L mitochondrial distribution, which is essential for its mitophagic activity. Importantly, the deletion of the BNIP3L TM domain does not affect its interaction with BCL2 but hampers the formation of homodimeric BNIP3L forms [27]. BNIP3L homodimers have been described two decades ago [4, 27], but the biological function of dimeric BNIP3L remains undetermined. We recently showed dimeric BNIP3L is required for mitophagy [15]. Point mutations on the TM domain disrupt BNIP3L dimer formation without affecting its mitochondrial localization. A monomeric BNIP3L mutant failed to induce mitophagy in CCCP-treated HeLa cells and ischemic neuronal cells. Additionally, we found that the dimeric form of BNIP3L is more prone to degradation by the proteasomes in ischemic brains, suggesting an intrinsic mechanism through which neuronal cells tightly limit mitophagy. In accordance with this finding, recent work by Novak et al. supports the essential role of the BNIP3L dimer in mitophagy induction [83]. The same mutation in the TM domain (G204A) led to attenuated LC3A binding and mitophagy defects. Interestingly, the authors provided an elegant mechanistic illustration of the formation of the BNIP3L dimer. The phosphorylated serine 212 prevents BNIP3L dimer formation, indicating phosphorylation of distinct BNIP3L serine residues have opposite effects on mitophagic activity. Of note, the S212 residue is located in the intermembrane space of the mitochondria, suggesting mitochondria-derived signaling regulates mitophagy. These discoveries found an alternative BNIP3L control of mitophagy through the formation of...
homodimers. However, it is unclear how the BNIP3L dimer triggers mitophagy and the molecular mechanisms underlying BNIP3L dimerization.

BNIP3L-mediated mitophagy is finely controlled by several mechanisms beyond Bnip3l transcription (Fig. 3). Recent evidence indicated posttranslational modifications and homodimerization of BNIP3L are key participants in its mitophagic activity. Further research is necessary to understand how these BNIP3L modifications affect mitophagy as a response to environmental changes and their physiological/pathological significance.

**CROSSTALK BETWEEN BNIP3L AND OTHER AUTOPHAGY/MITOPHAGY PATHWAYS**

Recent data indicated BNIP3L interplays with other autophagy-related pathways [42, 43, 52, 87]. Under hypoxia conditions, BNIP3L disrupts the BCL2–BECN1 complex by competitively binding with BCL2 via its BH3 domain, and the released BECN1 promotes the formation of autophagosomes [42, 43]. In a variety of cancer cell lines, BNIP3L regulation triggers autophagy and decreases cell death. Moreover, BNIP3L was shown to inhibit MTORC1 by preventing RHEB activity and subsequently induced autophagy. A recent study implied that dysfunctional mitochondria are unable to sustain synaptic homeostasis and increase oxidative damage. The modulating effects of RHEB by BNIP3L in eliminating neuronal axonal mitochondria, showing potential benefits in counteracting Alzheimer’s [47].

Beyond interactions with autophagy-related pathways, BNIP3L also interplays with mitophagy pathways. Cardiolipin is essential for maintaining the structural organization and function of mitochondrial membranes [88], and the accumulation of cardiolipin is accompanied by the upregulation of BNIP3L. PLD6 knockdown prevents BNIP3L-induced MTOR-RPS6KB activation. The crosstalk between BNIP3L and cardiolipin provides a possibility to treat insulin desensitization. BNIP3 and BNIP3L possess common features with the BH3-only protein subgroup of the BCL2 family. Using a stringent, high-throughput yeast two-hybrid system, researchers found that BNIP3 interacts with BNIP3L [89]. However, existing research suggested that BNIP3 and BNIP3L mediate parallel death and autophagy pathways. In patients with breast cancer brain metastases and uveal melanoma, BNIP3 but not BNIP3L may serve as a putative biomarker [90, 91]. Also, previous studies suggested that BNIP3 may be a promising therapeutic target of myocardial infarction, insulin resistance, and osteoarthritis [92–94]. In cases of cell stress, ΔΨm loss can promptly occur and be sensed by the PRKN/PARK2, thus enabling the mitophagic process. BNIP3L was proposed as a PARK2 substrate that recruits adapter proteins in autophagosomes after being ubiquitinated. Briefly, the degradation of BNIP3L attenuates mitophagy and causes injury to DA neurons and PD [58]. Additionally, BNIP3L also interacts with other proteins such as DOK5, EWSR1, RINT1, and ADIPQ [89, 95]. However, it is still unclear whether these interactions have biological significance.

**BNIP3L-MEDIATED MITOPHagy IN HUMAN DISEASES**

Mitochondria play key roles in producing energy, buffering calcium, synthesizing steroids, and regulating programmed cell death [96]. The dysregulation of mitochondria is closely related to a variety of human diseases [97]. Neurons have extremely high requirements for energy. Mitochondria dysfunction is intimately associated with neurological disorders [15, 98–102]. Particularly, mitophagy defects may underlie the pathogenesis of Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease [103–107]. Moreover, it has been documented that mitophagy dysregulation plays a critical role in tumorogenesis [108–110]. Therefore, it comes to a consensus that the disruption of mitophagy is highly involved in a variety of human diseases [97, 111, 112].

BNIP3L has been implicated in a variety of human diseases, including cancer, neurological, metabolic, and cardiovascular disorders. Mounting evidence supports the involvement of BNIP3L-mediated mitophagy in these disorders. Here, we focus on the role of autophagy/mitophagy activity of BNIP3L in human diseases by discussing recent studies in the field that shed light on the potential of targeting BNIP3L for therapeutics.

**Cancer**

The contribution of BNIP3L to cancer cells remains controversial. BNIP3L is recognized as a tumor suppressor gene and a link between BNIP3L-related autophagy/mitophagy activity and cancer cell death has recently been investigated. BNIP3L reportedly caused autophagic melanoma cell death by recruiting TR3 to mitochondria [55]. The RNA oncomir gene mir-30d promotes mitophagic melanoma cell death by recruiting TR3 to mitochondria [55]. The RNA oncomir gene mir-30d promotes mitophagic melanoma cell death by recruiting TR3 to mitochondria [55]. The RNA oncomir gene mir-30d promotes mitophagic melanoma cell death by recruiting TR3 to mitochondria [55]. The RNA oncomir gene mir-30d promotes mitophagic melanoma cell death by recruiting TR3 to mitochondria [55]. The RNA oncomir gene mir-30d promotes mitophagic melanoma cell death by recruiting TR3 to mitochondria [55]. The RNA oncomir gene mir-30d promotes mitophagic melanoma cell death by recruiting TR3 to mitochondria [55]. The RNA oncomir gene mir-30d promotes mitophagic melanoma cell death by recruiting TR3 to mitochondria [55]. The RNA oncomir gene mir-30d promotes mitophagic melanoma cell death by recruiting TR3 to mitochondria [55]. The RNA oncomir gene mir-30d promotes mitophagic melanoma cell death by recruiting TR3 to mitochondria [55]. The RNA oncomir gene mir-30d promotes mitophagic melanoma cell death by recruiting TR3 to mitochondria [55]. The RNA oncomir gene mir-30d promotes mitophagic melanoma cell death by recruiting TR3 to mitochondria [55].
Similarly, higher BNIP3L expression is associated with a better prognosis of acute myeloid leukemia (AML) and sensitized decitabine-induced cell demise without inducing apoptosis [115]. This process likely occurs via mitophagy regulation. In contrast, BNIP3L was considered as an oncogene that disrupts the interaction between BCL2 with BECN1. Accordingly, Bnip3l knockdown led to autophagy defects and increased cell mortality, which means BNIP3L-related autophagy might be related to survival in solid tumors in hypoxic environments [42, 43]. This idea was further supported by a transcriptional analysis indicating BNIP3L upregulation is closely linked with TNF-α resistance in breast cancer cells [116]. Additionally, BNIP3L was found to introduce XIAP into mitochondria through a yet- unidentified mechanism to degrade SMAC. This process can delay mitochondrial-dependent apoptosis in MCF-7 cells [32]. A growing amount of evidence showed that mitochondrial BNIP3L promotes the survival of glioblastoma cells and pancreatic cancer cells. BNIP3L-induced mitophagy alternates either glucose metabolism or mitochondrial OXPHOS status to adapt to the oncogenic environment [117, 118]. In AML cells, Bnip3l silencing leading to increased sensitivity to mitochondria- but not DNA-targeting drugs, also implies a potential link between BNIP3L-mediated mitophagy and cancer cell survival [119].

It must be emphasized that mitophagy reportedly plays a dual role in cancer biology [26, 120]. The level of BNIP3L is high in organoids derived from murine pancreatic intraepithelial neoplasia, thereby delaying progression of pancreatic ductal adenocarcinoma (PDAC) and suggests BNIP3L-mediated mitophagy promotes tumorigenesis [116]. However, a greater amount of evidence from different cancer cell lines and animal models showed BNIP3L-mediated mitophagy alters with the stage of tumor progression.

We also noted that BNIP3L-mediated mitophagy might play a role in anti-cancer treatment by regulating the formation of immunological memory. There is evidence that BNIP3L-mediated mitophagy is able to remove dysfunctional mitochondria and ROS accumulated in natural killer cells when proliferating. This is thought to promote cell survival during the transition to memory cells [39]. In CD8 + T cells, BNIP3L-mediated mitophagy deficiency causes superoxide accumulation in mitochondria and reduction of ATP synthesis, which inhibits the formation of effector memory and recall response [121].

Taken together, BNIP3L-mediated autophagy/mitophagy plays a complex role in the fate of cancer cells (Table 2 and Fig. 4). This complexity can be attributed to the heterogeneity of different types of cancer, the exposure to anti-cancer drugs, the distinct stages and dynamic niches of cancer progression, and the formation of immunological memory. Hence, it is still a pending question whether disturbing BNIP3L-mediated mitophagy represents a safe and efficient strategy in cancer therapy.

**Neurodegeneration**

Mitophagy has been recognized as essential for neuronal survival during neurodegeneration. The discovery that Parkinson’s disease (PD)-related genes Pink1 and Park2 participate in mitophagy highlighted how this process maintains the steady state of striatum dopaminergic neurons. However, Park2 deletion failed to recapitulate PD phenotypes in mice, implying other compensatory mechanisms exist to ensure mitophagy [122, 123]. While it is still debatable whether PARK2 is involved in BNIP3L-mediated mitophagy, recent evidence implied BNIP3L may compensate for mitophagy in PD. Accordingly, an Mptp-induced parkinsonism model Bnip3l was downregulated, but this could be reversed through neuroprotectant rescuing dopamine neuron death [124]. In a murine model carrying a GBA mutant, which is a genetic risk factor for PD, the Bnip3l dimer was reduced and this was accompanied by mitophagy dysfunction. Of note, the GBA mutation did not lead to PARK2 and ubiquitin alternations, implying less involvement of PARK2 in mitophagy defects [125]. In a murine model carrying a GBA mutant, which is a genetic risk factor for PD, the Bnip3l dimer was reduced and this was accompanied by mitophagy dysfunction. Of note, the GBA mutation did not lead to PARK2 and ubiquitin alternations, implying less involvement of PARK2 in mitophagy defects [59]. Even though these data suggested BNIP3L acts as an alternative molecular pathway restoring mitophagy in PD, it is still unclear whether BNIP3L is able to rescue dopaminergic neuronal death and PD symptoms, especially in the sporadic cases of PD.

BNIP3L upregulation was found in the cerebrospinal fluid of patients suffering from amyotrophic lateral sclerosis (ALS), a degenerative disorder of the motor neurons [126]. Likewise, BNIP3L upregulation was documented in the astrocytes of SOD1 mutant mice, a widely used model for ALS [127]. It was unraveled that whether upregulated BNIP3L can increase mitophagy activity, although some papers denoted that mitophagy defects might underlie ALS pathology [128, 129]. Besides PD and ALS, other studies indicated the potential involvement of BNIP3L-mediated autophagy/mitophagy in other neurodegenerative conditions, but the evidence is not conclusive [47, 130, 131]. Finally, there is no evidence indicating an association between Bnip3l mutation and neurodegeneration, although an emerging preliminary study implied its involvement in schizophrenia [132]. As compensation for mitophagy defects, it is likely that enhancing BNIP3L-mediated mitophagy offers a potential therapeutic strategy to treat neurodegenerative disorders.

**Acute brain injury**

Current evidence indicates BNIP3L is involved in acute brain injury disorder including cerebral ischemia, intracerebral hemorrhage (ICH), and traumatic brain injury, while most evidence indicates a proapoptotic role of BNIP3L. However, recent studies shed light on BNIP3L-mediated mitophagy in these diseases. The first report indicating BNIP3L upregulation and neuronal apoptosis in ischemic brain cells dates from 2005, before the gene was recognized as a mitophagy receptor [133]. Enhanced binding of BNIP3L with LC3 was observed in a delayed manner (72 h) after acute brain ischemia, suggesting excessive mitophagy may be correlated with delayed neuronal death [134]. Nevertheless, the contribution of BNIP3L-mediated mitophagy to brain ischemia was not determined by silencing or deleting the Bnip3l gene in animal cells. Our previous work revealed a neuroprotective role of mitophagy in acute brain ischemia in Bnip3l knockout mice [135, 136]. We demonstrated BNIP3L is required for ischemia-reperfusion-induced neuronal mitophagy and BNIP3L-mediated mitophagy offers protection against ischemic stroke by reinforcing clearance of damaged mitochondria [16]. In line with these findings, BNIP3L was found to be degraded by the proteasomes in permanent ischemic mice brains, which further leads to mitophagy defects. Blocking BNIP3L loss with the proteasomal inhibitor drug carfilzomib restored mitophagy and attenuated ischemic stroke [15]. These data emphasized the benefits of BNIP3L-mediated mitophagy in acute brain ischemia. Similarly, in a model evaluating traumatic brain injury in rats, neuronal BNIP3L reduction was found within 24 h after trauma. The overexpression of Bnip3l enhanced autophagic flux and attenuated traumatic brain injury, but it is still unclear whether mitophagy was also activated [60].

In contrast to studies on ischemic and traumatic brain injuries, there is a paucity of data indicating the involvement of BNIP3L-mediated mitophagy in intracerebral hemorrhage. It was shown that BNIP3L undergoes transient upregulation after brain hemorrhage in rats. However, the Bnip3l binding with BCL2 remained intact, suggesting minimal impacts on autophagy induction [137]. Alternatively, the bond between Bnip3l and p75 might stabilize Bnip3l on the outer mitochondrial membrane and promote neuronal apoptosis in the ICH brain [138]. However, these findings were argued since only a few neuronal cells showed features of apoptotic or autophagic death after ICH [139].
Overall, there is no strong evidence demonstrating a fundamental role of BNIP3L in any specific disorders, and there are no existing clinic approaches targeting BNIP3L. However, current evidence supports BNIP3L is involved in a variety of human diseases, from cancer to neurological disorders. Besides, BNIP3L-mediated mitophagy also involves in retinal ganglion cell development, intestinal inflammation, adult cardiac progenitor cells differentiation, and myocyte insulin resistance [57, 140–142]. Interestingly, an emerging study revealed BNIP3L mutations in human schizophrenia [132]. These studies highlighted the potential value of BNIP3L as a promising biomarker and drug target for specific human diseases.

**PERSPECTIVES**

It is increasingly clear that BNIP3L induces mitophagy by either activating autophagy or serving as a mitophagy receptor. Several studies showed BNIP3L is involved in diseases such as cancer, neurodegenerative disorders, and acute brain injury. BNIP3L plays a dual role in different kinds of cancer progression. In solid tumors (cell lines), breast cancer, glioblastoma, and pancreatic cancer, BNIP3L exacerbate cancer progression. However, it has an inverse role in the case of acute myeloid leukemia, melanoma, glioma, and Ewing sarcoma [32, 42, 43, 55, 68, 114–119]. These contrasting roles might be related to the unique metabolic environments of different tumors, but remained unclear. Additionally, it was reported that mitophagy also plays dual roles at different stages of cancer progression, despite a lack of studies addressing this specific question. In the case of neurodegenerative diseases such as Parkinson’s and ALS, BNIP3L accelerated disease progression [59, 122, 127]. However, due to the complexity of neurodegeneration and current technical limitations, it is not yet possible to thoroughly understand the underlying mechanisms. In the case of acute brain injury, BNIP3L protects the brain from damage. We found this is primarily...
related to BNIP3L-mediated mitophagy and independent of the PRKN/PARK2 [16]. We also showed BNIP3L dimer mediates mitophagy activity [15]. However, there are several important and outstanding questions in this case, including (but not limited to): (1) What are the key extra- and intracellular stimuli that trigger BNIP3L-mediated mitophagy? (2) How does BNIP3L regulate the extension and selectivity of mitophagy by sensing these stimuli? (It is possible BNIP3L responses to stimuli during phosphorylation and other posttranslational modifications). Nevertheless, the key amino acid residues and enzymes responsible for phosphorylation remain elusive. The identification of these enzymes might bring forward promising drug targets for BNIP3L-related human diseases, particularly neurological disorders. Unlike the case of PRKN/PARK2 and Parkinson’s disease, there is a paucity of data supporting the association between BNIP3L-mediated mitophagy and diseases, it is essential to identify key BNIP3L mutations to understand the biological function of this gene and provide the rationale for discovering novel therapeutic strategies.

DATA AVAILABILITY

The data used to support the findings of this study are available from the corresponding author upon request.

REFERENCES

1. Onishi M, Yamano K, Sato M, Matsuda N, Okamoto K. Molecular mechanisms and physiological functions of mitophagy. EMBO J. 2021;40:e104705.
2. Palikaras K, Lionaki E, Tavernarakis N. Mechanisms of mitophagy in cellular homeostasis, physiology and pathology. Nat Cell Biol. 2018;20:1013–22.
3. Xian H, Liou YC. Functions of outer mitochondrial membrane proteins: mediating the crosstalk between mitochondrial dynamics and mitophagy. Cell Death Differ. 2020;28:827–42.
4. Ghi N, Tokunaga A, Tsunoda H, Nakano K, Haraguchi K, Oda K, et al. A novel adenovirus E1819K-binding protein B5 inhibits apoptosis induced by Nip3 by forming a heterodimer through the C-terminal hydrophobic region. Cell Death Differ. 1999;6:314–35.
5. Yasuda M, Han JW, Dionne CA, Boyd JM, Chinnadurai G. BNIP3alpha: a human homolog of mitochondrial proapoptotic protein BNIP3. Cancer Res. 1999;59:533–7.
6. Zhang J, Ney PA. Mechanisms and biology of B-cell leukemia/lymphoma 2/adenovirus E1B-interacting protein 3 and Nip-like protein X. Antioxid Redox Signal. 2011;14:1959–69.
7. Schweers RI, Zhang J, Randall MS, Loyd MR, Li W, Dorsey FC, et al. NIX is required for programmed mitochondrial clearance during reticulocyte matura-
8. Xie Y, Liu J, Kang R, Tang D. Mitophagy receptors in tumor biology. Front Cell Dev Biol. 2020;8:594203.
9. Matsushima M, Fujitawa T, Takahashi E, Minaguchi T, Eguchi Y, Tsujimoto Y, et al. BNIP3 and genetic control of necrosis-like cell death through the mitochondrial perme-
10. Sowter HM, Ratcliffe PJ, Watson P, Greenberg AH, Harris AL. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res. 2001;61:6669–72.
11. Galvez AS, Brunskill EW, Munroe Y, Benner BJ, Regula KM, Kirschenbaum LA, et al. Distinct pathways regulate proapoptotic Nix and Bnip3 in cardiac stress. J Biol Chem. 2008;283:1442–5.
12. Novak I, Kirkin V, McEwan DG, Zhang J, Wild P, Rozenknop A, et al. Nix is a selective autophagy receptor for mitochondrial clearance. EMBO Rep. 2010;11:45–51.
13. Bruck RK. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci USA. 2000;97:9082–7.
14. Sowter HM, Ratcliffe PJ, Watson P, Greenberg AH, Harris AL. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res. 2001;61:6669–72.
15. Galvez AS, Brunskill EW, Munroe Y, Benner BJ, Regula KM, Kirschenbaum LA, et al. Distinct pathways regulate proapoptotic Nix and Bnip3 in cardiac stress. J Biol Chem. 2006;281:1442–8.
16. Bacon AL, Fox S, Turley H, Harris AL. Selective silencing of the hypoxia-inducible factor 1 target gene BNIP3 by histone deacetylation and methylation in colon-
17. Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell. 2011;147:728–41.
18. Kim KH, Lee MS. Autophagy—a key player in cellular and body metabolism. Nat Rev Endocrinol. 2014;10:322–37.
19. Yoo SM, Jung YK. A molecular approach to mitophagy and mitochondrial dynamics. Mol Cells. 2018;41:18–26.
20. Jin SM, Youle RJ. The accumulation of misfolded proteins in the mitochondrial matrix is sensed by PINK1 to induce PARK2/Parkin-mediated mitophagy of polarized mitochondria. Autophagy. 2013;9:1750–7.
21. Chen M, Chen Z, Wang Y, Tan Z, Zhu C, Li Y, et al. Mitophagy receptor FUNDC1 regulates mitochondrial dynamics and mitophagy. Autophagy. 2016;12:689–702.
22. Zhang J, Ney PA. Role of BNIP3 and NIX in cell death, autophagy, and mito-
23. Wei Y, Chiang WC, Sumpter R Jr., Mishra P, Levine B. Prohibitin 2 is an inner mitochondrial membrane mitophagy receptor. Cell. 2017;168:324–38. e10.
24. Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidel-
25. Y. Li et al.
26. Xie Y, Liu J, Kang R, Tang D. Mitophagy receptors in tumor biology. Front Cell Dev Biol. 2020;8:594203.
27. Imaizumi T, Shimizu S, Tagami S, Matsushima M, Nakamura Y, Yuki T, et al. Bcl-2/Bcl-X L: Bcl-2 interacting protein 3-like protein (Bnip3L) interacts with bcl-2/Bcl-X L and induces apoptosis by altering mitochondrial membrane permeability. Oncogene. 1999;18:4523–9.
28. Sowter HM, Ratcliffe PJ, Watson P, Greenberg AH, Harris AL. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res. 2001;61:6669–72.
29. Novak I, Kirkin V, McEwan DG, Zhang J, Wild P, Rozenknop A, et al. Nix is a selective autophagy receptor for mitochondrial clearance. EMBO Rep. 2010;11:45–51.
30. Bruck RK. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci USA. 2000;97:9082–7.
31. Sowter HM, Ratcliffe PJ, Watson P, Greenberg AH, Harris AL. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res. 2001;61:6669–72.
32. Calvino AS, Brunskill EW, Munroe Y, Benner BJ, Regula KM, Kirschenbaum LA, et al. Distinct pathways regulate proapoptotic Nix and Bnip3 in cardiac stress. J Biol Chem. 2006;281:1442–8.
33. Bacon AL, Fox S, Turley H, Harris AL. Selective silencing of the hypoxia-inducible factor 1 target gene BNIP3 by histone deacetylation and methylation in colorectal cancer. Oncogene. 2007;26:132–41.
34. Rogoz VV, Suzuki H, Marinovkic M, Lang V, Kato R, Kawasaki M, et al. Phosphorylation of the mitochondrial autophagy receptor Nix enhances its interaction with LC3 proteins. Sci Rep. 2017;7:1131.
35. Wu X, Zheng Y, Liu M, Li Y, Ma S, Tang W, et al. BNIP3L/NIX degradation leads to mitophagy deficiency in ischemic brains. Autophagy. 2020;20:71–13.
36. Yuan Y, Zheng Y, Zhang X, Chen Y, Wu X, Wu J, et al. BNIP3L/NIX-mediated mitophagy protects against ischemic brain injury independent of PARK2. Autophagy. 2017;13:1754–66.
60. Ma J, Shi R, Zhang Y, Shan H, Zhang Q, Yang X, et al. Nix/BNIP3L-dependent mitophagy accounts for airway epithelial cell injury induced by cigarette smoke. J Cell Physiol. 2019;234:4210–20.

61. Maturi MC, Ciriolo A, Tasdemir E, Vicencio JM, Tajeddine N, Hickman JA, et al. BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-XL. Autophagy. 2007;3:574–6.

62. Maturi MC, Le Tournemil G, Ciriolo A, Rain JC, Gautier F, Jun P, et al. Functional and physical interaction between Bcl-XL and a BH3-like domain in Beclin-1. EMBO J. 2007;26:2527–39.

63. Han S, Jeong YY, Sheshadri P, Su X, Cai Q. Mitophagy regulates integrity of mitochondria at synapses and is critical for synaptic maintenance. EMBO Rep. 2020;21:e49801.

64. Papandreou I, Lim AL, Laderoute K, Denko NC. Hypoxia signals autophagy in cancer cells via AMPK activity, independent of HIF-1, BNIP3, and BNIP3L. Cell Death Differ. 2008;15:1572–81.

65. Schwartz M, Mohrulder J, Ma P, Stoldt M, Thielmann Y, Stangler T, et al. Nix directly binds to GABARAP, a possible crosstalk between apoptosis and autophagy. Autophagy. 2009;5:690–8.

66. Zhang J, Loyd MR, Randall MS, Waddell MB, Kriwacki RW, Ney PA. A short linear motif in BNIP3L (NIX) mediates mitochondrial clearance in reticulocytes. Autophagy. 2012;8:1325–32.

67. Brennan LA, McGeal-Estrada R, Logan CM, Cvekl A, Menko AS, Kantorov M. BNIP3L/NIX is required for elimination of mitochondria, endoplasmic reticulum and Golgi apparatus during eye lens organelle-free zone formation. Exp Eye Res. 2018;174:173–84.

68. Gao F, Chen D, Si J, Hu Q, Qin Z, Fang M, et al. The mitochondrial protein BNIP3L is the substrate of PARK2 and mediates mitophagy in PARK1/PARK2 pathway. Hum Mol Genet. 2015;24:2528–38.

69. Chen Y, Lewis W, Diwan A, Cheng EH, Matkovic SJ, Dorn GW 2nd, et al. The mitochondrial protein BNIP3L is predictive of unfavorable prognosis in uveal melanoma. Med Sci Monit. 2018;24:4711–8.

70. Gubern C, Camos S, Ballesteros I, Rodriguez R, Romera VG, Canudas R, et al. miRNA expression is modulated over time after focal ischaemia: up-regulation of miR-347 promotes neuronal apoptosis. FEBS J. 2013;280:2333–46.

71. Zhang Z, Hong Y, Xiang D, Zhu P, Wu E, Li W, et al. MicroRNA-302/367 cluster governs hESC self-renewal by dually regulating cell cycle and autophagy pathways. Stem Cell Rep. 2015;4:645–57.

72. Mughal W, Martens F, Field J, Chapman D, Huang J, Rattan S, et al. Myocardin regulates mitochondrial calcium homeostasis and prevents permeability transition. Cell Death Differ. 2018;25:1732–48.

73. Li W, Chen H, Li S, Lin G, Feng D. Exploring microRNAs on NIX-dependent autophagy. Methods Mol Biol. 2018;1759:1–22.

74. Veron V, Marandel L, Liu J, Velez EJ, Lepais O, Panerati S, et al. DNA methylation of the promoter region of bnip3 and bnip3l genes induced by metabolic programming. BMC Genomics. 2019;20:1667.

75. Salvi M, Sarno S, Cesario L, Nakamura H, Pinna LA. Extraordinary pleiotropy of protein kinase CK2 revealed by weblogo phosphoproteome analysis. Biochim Biophys Acta. 2009;1793:847–59.

76. Chen G, Han Z, Feng D, Chen Y, Chen L, Wu H, et al. A regulatory signaling loop comprising the PGAM5 phosphatase and CK2 controls receptor-mediated mitophagy. Mol Cell. 2014;54:362–77.

77. Naem S, Qi Y, Tian Y, Zhang Y. NIX compromises lost role of parkin in cd-induced mitophagy in HeLa cells through phosphorylation. Toxicol Lett. 2020;326:1–10.

78. Marinkovic M, Sprung M, Novak I. Dimerization of mitophagy receptor BNIP3L- NIX is essential for recruitment of autophagic machinery. Cell Death Differ. 2017;24:1232–43.

79. Chen Z, Liu L, Chen Y, Cheng Q, Li Y, Wu H, Zhang W, et al. Mitochondrial E3 ligase MARCH5 regulates FUNDC1 to modulate mitophagy. Cell Death Dis. 2015;6:e1955.

80. Li J, Qi W, Chen G, Feng D, Liu J, Ma B, et al. Mitochondrial outer-membrane E3 ligase MUL1 ubiquinatesULK1 and regulates selene-induced mitophagy. Autophagy. 2015;11:1216–29.

81. Di Rita A, Peschiaroli A, PA D, Strobbe D, Hu Z, Gruber J, et al. HUWE1 E3 ligase promotes PARK1/PARKin-independent mitophagy by regulating AMBRA1 activation via IKKalpha. Nat Commun. 2018;9:3755.

82. Han S, Jeong YY, Sheshadri P, Su X, Cai Q. Mitophagy regulates integrity of mitochondria at synapses and is critical for synaptic maintenance. EMBO Rep. 2020;21:e49801.
1. Chun BY, Rizzo JF 3rd. Dominant optic atrophy and Leber hereditary optic neuropathy: update on clinical features and current therapeutic approaches. Semin Pediatr Neurol. 2017;24:129–34.

2. Zhang X, Yan H, Yuan Y, Gao J, Shen Z, Cheng Y, et al. Cerebral ischemia-reperfusion-induced autophagy protects against neuronal injury by mitochondrial clearance. Autophagy. 2013;9:1321–8.

3. Ma Z, Wang D, Weng J, Zhang S, Zhang Y. BNIP3 decreases the LPS-induced inflammation and apoptosis of chondrocytes by promoting the development of autophagy. J Orthop Surg Res. 2020;15:258.

4. Rodrigo R, Mendis N, Ibrahim M, Ma C, Kreinin E, Roma A, et al. Knockdown of BNIP3L or SQSTM1 alters cellular response to mitophagy-targeted drugs. Autophagy. 2019;15:900–7.

5. Miller DR, Thorburn D. Autophagy and organellar homeostasis in cancer. Developmental cell. 2021;56:906–18.

6. Gupta SS, Sharp R, Hofferek C, Kusi L, Dorn GW 2nd, Wang J, et al. NIX-mediated mitophagy promotes effector memory formation in antigen-specific CD8(+) T cells. Cell Rep. 2019;29:1862–77, e7.

7. Zou S, Rizzo JF 3rd, Lee SM, et al. Mitophagy in degenerative joint diseases. J Orthop Res. 2018;36:925–31.

8. Xiong Y. Li et al. © 2022 Springer Nature Limited. This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/).

9. Rodrigo R, Mendis N, Ibrahim M, Ma C, Kreinin E, Roma A, et al. Knockdown of BNIP3L or SQSTM1 alters cellular response to mitophagy-targeted drugs. Autophagy. 2019;15:900–7.

10. Miller DR, Thorburn D. Autophagy and organellar homeostasis in cancer. Developmental cell. 2021;56:906–18.

11. Gupta SS, Sharp R, Hofferek C, Kusi L, Dorn GW 2nd, Wang J, et al. NIX-mediated mitophagy promotes effector memory formation in antigen-specific CD8(+) T cells. Cell Rep. 2019;29:1862–77, e7.

12. Zou S, Rizzo JF 3rd, Lee SM, et al. Mitophagy in degenerative joint diseases. J Orthop Res. 2018;36:925–31.

13. Xiong Y. Li et al. © 2022 Springer Nature Limited. This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/).

14. Rodrigo R, Mendis N, Ibrahim M, Ma C, Kreinin E, Roma A, et al. Knockdown of BNIP3L or SQSTM1 alters cellular response to mitophagy-targeted drugs. Autophagy. 2019;15:900–7.

15. Miller DR, Thorburn D. Autophagy and organellar homeostasis in cancer. Developmental cell. 2021;56:906–18.

16. Gupta SS, Sharp R, Hofferek C, Kusi L, Dorn GW 2nd, Wang J, et al. NIX-mediated mitophagy promotes effector memory formation in antigen-specific CD8(+) T cells. Cell Rep. 2019;29:1862–77, e7.

17. Zou S, Rizzo JF 3rd, Lee SM, et al. Mitophagy in degenerative joint diseases. J Orthop Res. 2018;36:925–31.

18. Xiong Y. Li et al. © 2022 Springer Nature Limited. This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/).

19. Rodrigo R, Mendis N, Ibrahim M, Ma C, Kreinin E, Roma A, et al. Knockdown of BNIP3L or SQSTM1 alters cellular response to mitophagy-targeted drugs. Autophagy. 2019;15:900–7.

20. Miller DR, Thorburn D. Autophagy and organellar homeostasis in cancer. Developmental cell. 2021;56:906–18.

21. Gupta SS, Sharp R, Hofferek C, Kusi L, Dorn GW 2nd, Wang J, et al. NIX-mediated mitophagy promotes effector memory formation in antigen-specific CD8(+) T cells. Cell Rep. 2019;29:1862–77, e7.

22. Zou S, Rizzo JF 3rd, Lee SM, et al. Mitophagy in degenerative joint diseases. J Orthop Res. 2018;36:925–31.

23. Xiong Y. Li et al. © 2022 Springer Nature Limited. This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/).

24. Rodrigo R, Mendis N, Ibrahim M, Ma C, Kreinin E, Roma A, et al. Knockdown of BNIP3L or SQSTM1 alters cellular response to mitophagy-targeted drugs. Autophagy. 2019;15:900–7.

25. Miller DR, Thorburn D. Autophagy and organellar homeostasis in cancer. Developmental cell. 2021;56:906–18.

26. Gupta SS, Sharp R, Hofferek C, Kusi L, Dorn GW 2nd, Wang J, et al. NIX-mediated mitophagy promotes effector memory formation in antigen-specific CD8(+) T cells. Cell Rep. 2019;29:1862–77, e7.

27. Zou S, Rizzo JF 3rd, Lee SM, et al. Mitophagy in degenerative joint diseases. J Orthop Res. 2018;36:925–31.

28. Xiong Y. Li et al. © 2022 Springer Nature Limited. This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/).

29. Rodrigo R, Mendis N, Ibrahim M, Ma C, Kreinin E, Roma A, et al. Knockdown of BNIP3L or SQSTM1 alters cellular response to mitophagy-targeted drugs. Autophagy. 2019;15:900–7.

30. Miller DR, Thorburn D. Autophagy and organellar homeostasis in cancer. Developmental cell. 2021;56:906–18.
AUTHOR CONTRIBUTIONS
X.Z., X.W., Y.Y., Z.S., and Y.Z. conceived and designed the study; X.Z., Y.Li., and W.Z. performed the literature investigation and wrote the manuscript; and Y.Li., Y.Lu., L.P., S.M., J.W., and Z.C. edited and revised the paper. All authors read and approved the final manuscript.

FUNDING
This work was funded by the National Natural Science Foundation of China (81822044 and 81773703) and Zhejiang Provincial Natural Science Foundation (Z21H310002).

COMPETING INTERESTS
The authors declared no competing interests. We declare that we do not have any commercial or associative interest that represents a conflict of interest in connection with the work submitted.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to Zhong Chen or Xiangnan Zhang.